Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy

NCT00147355 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT00147355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00147355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy
Lead sponsor
Kirby Institute
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2005
Completion date
December 31, 2008
Enrollment
28 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections